Angiogenesis and multiple myeloma

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Multiple myeloma bone marrow exhibits increased microvessel density.
• This is driven by elevated pro-angiogenic molecules and suppressed inhibitors, termed the 'angiogenic switch'.

Purpose of the Study:

• To review the role of angiogenesis in multiple myeloma.
• To outline pro-angiogenic factors from myeloma cells and the microenvironment.
• To explain mechanisms of the myeloma-induced angiogenic switch.

Main Methods:

• Literature review and data synthesis on angiogenesis in multiple myeloma.
• Analysis of pro-angiogenic factors and their regulation.
• Investigation of hypoxia and specific gene roles (HIF-1α, IOF4, HOXB7).

Main Results:

• Increased bone marrow angiogenesis in multiple myeloma results from aberrant angiogenic factor expression by myeloma cells.
• Myeloma cell activity enhances pro-angiogenic activity in normal plasma cells.
• Hypoxia, via hypoxia-inducible factor-1α (HIF-1α), contributes significantly to the angiogenic microenvironment.

Conclusions:

• Multiple myeloma angiogenesis is a complex process involving myeloma cells, the microenvironment, and hypoxia.
• Aberrant expression of angiogenic factors and related genes are key drivers.
• Several pro-angiogenic molecules and genes represent potential therapeutic targets.